JP7822946B2 - コロナウイルス感染の治療 - Google Patents

コロナウイルス感染の治療

Info

Publication number
JP7822946B2
JP7822946B2 JP2022554382A JP2022554382A JP7822946B2 JP 7822946 B2 JP7822946 B2 JP 7822946B2 JP 2022554382 A JP2022554382 A JP 2022554382A JP 2022554382 A JP2022554382 A JP 2022554382A JP 7822946 B2 JP7822946 B2 JP 7822946B2
Authority
JP
Japan
Prior art keywords
patients
sars
cov
coronavirus
covid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517920A (ja
JP2023517920A5 (https=
Inventor
ベン－アッシャー，ドゥロール
ファシ，レザ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of JP2023517920A publication Critical patent/JP2023517920A/ja
Publication of JP2023517920A5 publication Critical patent/JP2023517920A5/ja
Application granted granted Critical
Publication of JP7822946B2 publication Critical patent/JP7822946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022554382A 2020-03-10 2021-03-08 コロナウイルス感染の治療 Active JP7822946B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062987429P 2020-03-10 2020-03-10
US62/987,429 2020-03-10
US202063003601P 2020-04-01 2020-04-01
US63/003,601 2020-04-01
US202063034817P 2020-06-04 2020-06-04
US63/034,817 2020-06-04
US202063074799P 2020-09-04 2020-09-04
US63/074,799 2020-09-04
US202063125427P 2020-12-15 2020-12-15
US63/125,427 2020-12-15
PCT/IB2021/000131 WO2021181157A1 (en) 2020-03-10 2021-03-08 Treatment of coronavirus infection

Publications (3)

Publication Number Publication Date
JP2023517920A JP2023517920A (ja) 2023-04-27
JP2023517920A5 JP2023517920A5 (https=) 2024-02-01
JP7822946B2 true JP7822946B2 (ja) 2026-03-03

Family

ID=76548186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554382A Active JP7822946B2 (ja) 2020-03-10 2021-03-08 コロナウイルス感染の治療

Country Status (11)

Country Link
US (6) US11052073B1 (https=)
EP (1) EP4117630A4 (https=)
JP (1) JP7822946B2 (https=)
KR (1) KR20220151613A (https=)
CN (2) CN117695284B (https=)
AU (1) AU2021235304A1 (https=)
BR (1) BR112022017923A2 (https=)
CA (1) CA3174438A1 (https=)
IL (1) IL295658A (https=)
MX (1) MX2022011173A (https=)
WO (1) WO2021181157A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN117695284B (zh) 2020-03-10 2025-06-17 红山生物医药有限公司 冠状病毒感染的治疗
US11471448B2 (en) * 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN113398219A (zh) * 2021-06-30 2021-09-17 广州白云山星群(药业)股份有限公司 橘红痰咳浸膏在制备抑制人冠状病毒感染的药物中的用途
EP4286851A1 (en) 2022-06-01 2023-12-06 Universität Wien Methods and means for molecular characterization of post-viral fatigue syndrome
WO2025133697A2 (en) * 2023-12-20 2025-06-26 Redhill Biopharma Ltd. Combination therapy for inhibition of ebolavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150126564A1 (en) 2011-06-01 2015-05-07 The Curators Of The University Of Missouri Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections
JP2017531673A (ja) 2014-10-24 2017-10-26 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． １本鎖ｒｎａウイルス複製を阻害するための治療
JP2023521630A (ja) 2020-04-02 2023-05-25 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． コロナウイルス感染症の処置及び／又は予防のための組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342018B2 (en) 1998-07-20 2008-03-11 Wilex Ag Urokinase inhibitors and uses thereof
US6624169B1 (en) 1998-07-20 2003-09-23 Wilex Biotechnology Gmbh Urokinase inhibitors
AU9059798A (en) 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors
DE50211672D1 (de) 2001-03-21 2008-03-27 Wilex Ag Urokinase-inhibitoren
CH695999A5 (de) 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
WO2004011449A2 (de) 2002-07-25 2004-02-05 Wilex Ag Verfahren zur herstellung von phenylalanin-derivaten
DE10238048A1 (de) 2002-07-25 2004-02-05 Wilex Ag Verfahren zur Herstellung von Phenylalanin-Derivaten
US9770349B2 (en) * 2002-11-13 2017-09-26 University Of Virginia Patent Foundation Nanoporous stents with enhanced cellular adhesion and reduced neointimal formation
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
RU2234313C1 (ru) 2003-06-04 2004-08-20 Кривошеин Юрий Семенович Средство инактивации коронавирусов
GB0420874D0 (en) 2004-09-20 2004-10-20 Swetree Technologies Ab Modulation of flowering time and growth cessation in perennial plants
DE102004045720A1 (de) 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
BRPI0516106B1 (pt) 2004-10-14 2021-08-24 Wilex Ag Métodos para purificação e preparação de derivados de 3-hidroxiamidinofenilalanina, e para produção de derivados de 3-amidinofenilalanina
DE102004057195A1 (de) 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US8324237B2 (en) 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
ES2528451T3 (es) 2005-06-17 2015-02-10 Apogee Biothechnology Corporation Inhibidores de esfingosina cinasa
WO2015161908A1 (en) * 2014-03-11 2015-10-29 Ludwig-Maximilians-Universität München Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections
DK3297438T3 (da) * 2015-05-21 2022-01-17 Chemocentryx Inc Ccr2-modulatorer
WO2017060771A2 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
US10195188B2 (en) * 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
US10251888B2 (en) * 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
CN117695284B (zh) * 2020-03-10 2025-06-17 红山生物医药有限公司 冠状病毒感染的治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150126564A1 (en) 2011-06-01 2015-05-07 The Curators Of The University Of Missouri Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections
JP2017531673A (ja) 2014-10-24 2017-10-26 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． １本鎖ｒｎａウイルス複製を阻害するための治療
JP2023521630A (ja) 2020-04-02 2023-05-25 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． コロナウイルス感染症の処置及び／又は予防のための組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Daisuke YAMANE et al.，"Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation"，Nature Medicine，2014年07月27日，Vol. 20, No. 8，p.927-935，DOI: 10.1038/nm.3610
Liying DONG et al.，"Discovering drugs to treat coronavirus disease 2019 (COVID-19)"，Drug Discoveries & Therapeutics，2020年02月29日，Vol. 14, No. 1，p.58-60，DOI: 10.5582/ddt.2020.01012
Markus HOFFMANN et al.，"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"，Cell，2020年04月，Vol. 181, No. 2，p.271-280.e8，DOI: 10.1016/j.cell.2020.02.052

Also Published As

Publication number Publication date
US11918560B2 (en) 2024-03-05
CN117695284A (zh) 2024-03-15
IL295658A (en) 2022-10-01
US11052073B1 (en) 2021-07-06
US12551469B2 (en) 2026-02-17
CN115515560A (zh) 2022-12-23
US11045453B1 (en) 2021-06-29
KR20220151613A (ko) 2022-11-15
JP2023517920A (ja) 2023-04-27
CN115515560B (zh) 2023-12-15
CN117695284B (zh) 2025-06-17
MX2022011173A (es) 2022-10-18
CA3174438A1 (en) 2021-09-16
US20240350461A1 (en) 2024-10-24
US20210299108A1 (en) 2021-09-30
US12502381B2 (en) 2025-12-23
AU2021235304A1 (en) 2022-10-06
EP4117630A1 (en) 2023-01-18
US11364227B2 (en) 2022-06-21
BR112022017923A2 (pt) 2022-10-18
EP4117630A4 (en) 2024-07-03
WO2021181157A1 (en) 2021-09-16
US20220031682A1 (en) 2022-02-03
US20210322390A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP7822946B2 (ja) コロナウイルス感染の治療
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CN116133657A (zh) 治疗covid-19疾病的新组合物和方法
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP7840570B2 (ja) コロナウイルス感染症の処置のための方法
TW202320778A (zh) 新型冠狀病毒感染症治療劑
RU2837859C1 (ru) Лечение коронавирусной инфекции
JP2023526200A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の予防または治療のための適合溶質
KR20230021009A (ko) 항바이러스 치료로서의 아젤라스틴
WO2021200651A1 (ja) コロナウイルス感染症治療剤
US12115150B2 (en) Biomarkers of coronavirus pneumonia
KR20220151181A (ko) 코로나바이러스 감염의 치료에 사용하기 위한 화합물
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
WO2023192779A2 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections
WO2025235945A1 (en) Methods of treating viral infections using a fusion inhibitor
WO2025210119A1 (en) Pi3k and/or mtor inhibitors for treating viral disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260218

R150 Certificate of patent or registration of utility model

Ref document number: 7822946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150